

## PHYSICIAN PRESCRIBING INFORMATION

### NAME OF THE MEDICINAL PRODUCT

#### Nurtec ODT

Orally disintegrating tablets

### QUALITATIVE AND QUANTITATIVE COMPOSITION

Each orally disintegrating tablet contains 75 mg rimegepant (equivalent to 85.65 mg rimegepant sulfate).

For the full list of excipients, *see Description (11)*.

### PHARMACEUTICAL FORM

Orally disintegrating tablets

## 1 THERAPEUTIC INDICATIONS

NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the:

- Acute treatment of migraine with or without aura in adults
- Preventive treatment of episodic migraine in adults\_

## 2 DOSAGE AND ADMINISTRATION

### 2.1 Recommended Dosing for Acute Treatment of Migraine

The recommended dose of NURTEC ODT is 75 mg taken orally, as needed.

The maximum dose in a 24-hour period is 75 mg. The safety of using more than 18 doses in a 30-day period has not been established.

### 2.2 Recommended Dosing for Preventive Treatment of Episodic Migraine

The recommended dosage of NURTEC ODT is 75 mg taken orally every other day.

### 2.3 Administration Information

Instruct the patient on the following administration instructions:

- Use dry hands when opening the blister pack.
- Peel back the foil covering of one blister and gently remove the orally disintegrating tablet (ODT). Do not push the ODT through the foil.
- As soon as the blister is opened, remove the ODT and place on the tongue; alternatively, the ODT may be placed under the tongue.
- The ODT will disintegrate in saliva so that it can be swallowed without additional liquid.
- Take the ODT immediately after opening the blister pack. Do not store the ODT outside the blister pack for future use.

#### **2.4 Concomitant Administration with Strong or Moderate CYP3A4 Inhibitors**

Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4. Avoid another dose of NURTEC ODT within 48 hours when it is concomitantly administered with moderate inhibitors of CYP3A4 [see *Drug Interactions (7.1), Clinical Pharmacology (12.3)*].


#### **2.5 Concomitant Administration with Strong or Moderate CYP3A Inducers**

Avoid concomitant administration of NURTEC ODT with strong or moderate inducers of CYP3A, which may lead to loss of efficacy of NURTEC ODT [see *Drug Interactions (7.2), Clinical Pharmacology (12.3)*].

#### **2.6 Concomitant Administration with Potent Inhibitors of P-gp**

Avoid another dose NURTEC ODT within 48 hours when it is concomitantly administered with potent inhibitors of P-gp [see *Drug interaction (7.3), Clinical Pharmacology (12.3)*].

### **3 DOSAGE FORMS AND STRENGTHS**

Orally disintegrating tablets: white to off-white, circular, and debossed with the symbol , each containing 75 mg of rimegepant.

### **4 CONTRAINDICATIONS**

Hypersensitivity to the active substance or to any of the excipients listed in section 11.

*Reactions have included anaphylaxis and delayed serious hypersensitivity [see Warnings and Precautions (5.1)].*

### **5 WARNING AND PRECAUTIONS**

#### **5.1 Hypersensitivity Reactions**

*Serious hypersensitivity reactions, including anaphylaxis, dyspnea and rash, have occurred in patients treated with NURTEC ODT. Hypersensitivity reactions can occur days after administration, and delayed serious hypersensitivity has occurred. If a hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy [see Contraindications (4) and Adverse Reactions (6.1, 6.2)].*

#### **5.2 Hypertension**

Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including NURTEC ODT, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension and, in some cases, hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. NURTEC ODT was discontinued in many of the reported cases.

Monitor patients treated with NURTEC ODT for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of NURTEC ODT is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

### 5.3 Raynaud's Phenomenon

Development of Raynaud's phenomenon and recurrence or worsening of pre-existing Raynaud's phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including NURTEC ODT.

In reported cases with small molecule CGRP antagonists, symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms.

NURTEC ODT should be discontinued if signs or symptoms of Raynaud's phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud's phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

## 6 ADVERSE REACTIONS

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Hypersensitivity Reactions *[see Warnings and Precautions (5.1)]*

- Hypertension *[see Warnings and Precautions (5.2)]*
- Raynaud's Phenomenon *[see Warnings and Precautions (5.3)]*

### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

#### Acute Treatment of Migraine

The safety of NURTEC ODT for the acute treatment of migraine in adults has been evaluated in a randomized, double-blind, placebo-controlled trial (Study 1) in 682 patients with migraine who received one 75 mg dose of NURTEC ODT *[see Clinical Studies (14)]*. Approximately 85% were female, 74% were White, 21% were Black, and 17% were Hispanic or Latino. The mean age at study entry was 40 years (range 18-75 years of age).

Long-term safety was assessed in an open-label extension study using a different oral dosage form of rimegepant. That study evaluated 1,798 patients, dosing intermittently for up to one year, including 1,131 patients who were exposed to rimegepant 75 mg for at least 6 months, and 863 who were exposed for at least one year, all of whom treated an average of at least two migraine attacks per month.

The most common adverse reaction in Study 1 was nausea (2% in patients who received NURTEC ODT compared to 0.4% of patients who received placebo).

Hypersensitivity, including dyspnea and severe rash, occurred in less than 1% of patients treated with NURTEC ODT *[see Contraindications (4) and Warnings and Precautions (5.1)]*.

## Preventive Treatment of Episodic Migraine

The safety of NURTEC ODT for the preventive treatment of episodic migraine in adults has been established in a randomized, double-blind, placebo-controlled trial with an open-label extension (Study 2) using a different oral dosage form of rimegepant [see *Clinical Studies (14)*]. In the 12-week, double-blind treatment period, 370 patients with migraine received one 75 mg dose of rimegepant every other day. Approximately 81% were female, 80% were White, 17% were Black, and 28% were Hispanic or Latino. The mean age at study entry was 41 years (range 18-74 years of age). Long-term safety was assessed in an open-label extension study that included 603 patients who were treated for up to one year. Overall, 527 patients were exposed to rimegepant 75 mg for at least 6 months, and 311 were exposed for at least one year.

The most common adverse reactions (occurring in at least 2% of rimegepant-treated patients and at a frequency of at least 1% higher than placebo) in Study 2 were nausea (2.7% in patients who received rimegepant compared with 0.8% of patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received rimegepant compared with 0.8% of patients who received placebo).

## **6.2 Postmarketing Experience**

The following adverse reactions have been identified during postapproval use of NURTEC ODT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

*Immune System Disorders:* Hypersensitivity (e.g., anaphylaxis) [see *Contraindications (4)* and *Warnings and Precautions (5.1)*]

*Vascular Disorders:* Hypertension [see *Warnings and Precautions (5.2)*], Raynaud's phenomenon [see *Warnings and Precautions (5.3)*].

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: <https://sideeffects.health.gov.il>

## **7 DRUG INTERACTIONS**

### **7.1 CYP3A4 Inhibitors**

Concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4 results in a significant increase in rimegepant exposure. Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4 [see *Clinical Pharmacology (12.3)*].

Concomitant administration of NURTEC ODT with moderate inhibitors of CYP3A4 may result in increased exposure of rimegepant. Avoid another dose of NURTEC ODT within 48 hours when it is concomitantly administered with moderate inhibitors of CYP3A4 [see *Clinical Pharmacology (12.3)*].

### **7.2 CYP3A Inducers**

Concomitant administration of NURTEC ODT with strong or moderate inducers of CYP3A can result in a significant reduction in rimegepant exposure, which may lead to loss of efficacy of NURTEC ODT.

Avoid concomitant administration of NURTEC ODT with strong or moderate inducers of CYP3A [see *Clinical Pharmacology* (12.3)].

### 7.3

#### P-gp Inhibitors

Concomitant administration of NURTEC ODT with potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) may result in increased exposure of rimegepant. Avoid another dose of NURTEC ODT within 48 hours when it is concomitantly administered with potent inhibitors of P-gp [see *Clinical Pharmacology* (12.3)].

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### Risk Summary

There are no adequate data on the developmental risk associated with the use of NURTEC ODT in pregnant women. In animal studies, oral administration of rimegepant during organogenesis resulted in adverse effects on development in rats (decreased fetal body weight and increased incidence of skeletal variations) at exposures greater than those used clinically and which were associated with maternal toxicity.

(see Data).

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The estimated rate of major birth defects (2.2 to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.

#### Clinical Considerations

##### *Disease-Associated Maternal and/or Embryo/Fetal Risk*

Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.

#### Data

##### *Animal Data*

Oral administration of rimegepant (0, 10, 60, or 300 mg/kg/day) to pregnant rats during the period of organogenesis resulted in decreased fetal body weight and an increased incidence of fetal skeletal variations at the highest dose tested (300 mg/kg/day), which was associated with maternal toxicity. Plasma exposures (AUC) at the no-effect dose (60 mg/kg/day) for adverse effects on embryofetal development were approximately 45 times that in humans at the maximum recommended human dose (MRHD) of 75 mg/day.

Oral administration of rimegepant (0, 10, 25, or 50 mg/kg/day) to pregnant rabbits during the period of organogenesis resulted in no adverse effects on embryofetal development. The highest dose tested (50 mg/kg/day) was associated with plasma exposures (AUC) approximately 10 times that in humans at the MRHD.

Oral administration of rimegepant (0, 10, 25, or 60 mg/kg/day) to rats throughout gestation and lactation, resulted in no effects on pre- or postnatal development. The highest dose tested (60 mg/kg/day) was associated with plasma exposures (AUC) approximately 24 times that in humans at the MRHD.

## 8.2 Lactation

### Risk Summary

A lactation study was conducted, and the results have established a relative infant dose of less than 1% of the maternal weight-adjusted dose and the milk-to-plasma ratio of 0.20 (see Data). These data support that transfer of rimegepant into breastmilk is low. There are no data on the effects of rimegepant on a breastfed infant or on milk production.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NURTEC ODT and any potential adverse effects on the breastfed infant from NURTEC ODT or from the underlying maternal condition. Data

A study was conducted in twelve healthy adult lactating women who were between 2 weeks and 6 months postpartum and were administered a single oral dose of rimegepant 75 mg. The relative infant dose was <1%. The average milk to plasma ratio was 0.20

## 8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

## 8.5 Geriatric Use

In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects. Clinical studies of NURTEC ODT did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

## 8.6 Hepatic Impairment

No dosage adjustment of NURTEC ODT is required in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Plasma concentrations of rimegepant were significantly higher in subjects with severe (Child-Pugh C) hepatic impairment. Avoid use of NURTEC ODT in patients with severe hepatic impairment [see *Clinical Pharmacology (12.3)*].

## 8.7 Renal Impairment


No dosage adjustment of NURTEC ODT is required in patients with mild, moderate, or severe renal impairment. NURTEC ODT has not been studied in patients with end-stage renal disease and in patients on dialysis. Avoid use of NURTEC ODT in patients with end-stage renal disease (CL<sub>cr</sub> < 15 mL/min) [see *Clinical Pharmacology (12.3)*].

## 10 OVERDOSAGE

There is limited clinical experience with NURTEC ODT overdose. Treatment of an overdose of NURTEC ODT should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. No specific antidote for the treatment of rimegepant overdose is available. Rimegepant is unlikely to be significantly removed by dialysis because of high serum protein binding [see *Clinical Pharmacology (12.3)*].

## 11 DESCRIPTION

NURTEC ODT contains rimegepant sulfate, a calcitonin gene-related peptide receptor antagonist. Rimegepant sulfate is described chemically as (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate sesquihydrate and its structural formula is:



Its empirical formula is C<sub>28</sub>H<sub>28</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> 0.5 H<sub>2</sub>SO<sub>4</sub> 1.5 H<sub>2</sub>O, representing a molecular weight of 610.63. Rimegepant free base has a molecular weight of 534.56. Rimegepant sulfate is a white to off-white, crystalline solid that is slightly soluble in water.

NURTEC ODT (orally disintegrating tablets) is for sublingual or oral use and contains 85.7 mg rimegepant sulfate, equivalent to 75 mg rimegepant free base, and the following inactive ingredients: benzyl alcohol, eucalyptol, gelatin, limonene, mannitol, menthol, menthone, menthyl acetate, sucralose micronized, and vanillin.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Rimegepant is a calcitonin gene-related peptide receptor antagonist.

### 12.2 Pharmacodynamics

The relationship between pharmacodynamic activity and the mechanism(s) by which rimegepant exerts its clinical effects is unknown.

No clinically relevant differences in resting blood pressure were observed when rimegepant was concomitantly administered with sumatriptan (12 mg subcutaneous, given as two 6 mg doses separated by one hour) compared with sumatriptan alone to healthy volunteers.

#### Cardiac Electrophysiology

At a single dose 4 times the recommended dose, rimegepant does not prolong the QT interval to any clinically relevant extent.

### 12.3 Pharmacokinetics

#### Absorption

Following oral administration of NURTEC ODT, rimegepant is absorbed with the maximum concentration at 1.5 hours. The absolute oral bioavailability of rimegepant is approximately 64%.

#### *Effects of Food*

Following administration of NURTEC ODT under fed conditions with a high-fat or low-fat meal,  $T_{max}$  was delayed by approximately 1 to 1.5 hours. A high-fat meal reduced  $C_{max}$  by 42 to 53% and AUC by 32 to 38%. A low-fat meal reduced  $C_{max}$  by 36% and AUC by 28%. NURTEC ODT was administered without regard to food in clinical safety and efficacy studies. The impact of the reduction in rimegepant exposure because of administration with food on its efficacy is unknown.

#### Distribution

The steady state volume of distribution of rimegepant is 120 L. Plasma protein binding of rimegepant is approximately 96%.

#### Elimination

##### *Metabolism*

Rimegepant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9. Rimegepant is the primary form (~77%) with no major metabolites (i.e., > 10%) detected in plasma.

##### *Excretion*

The elimination half-life of rimegepant is approximately 11 hours in healthy subjects. Following oral administration of [ $^{14}$ C]-rimegepant to healthy male subjects, 78% of the total radioactivity was recovered in feces and 24% in urine. Unchanged rimegepant is the major single component in excreted feces (42%) and urine (51%).

#### Specific Populations

##### *Renal Impairment*

In a dedicated clinical study comparing the pharmacokinetics of rimegepant in subjects with mild (estimated creatinine clearance [CLcr] 60-89 mL/min), moderate (CLcr 30-59 mL/min), and severe (CLcr 15-29 mL/min) renal impairment to that with normal subjects (healthy matched control), the exposure of rimegepant following single 75 mg dose was approximately 40% higher in subjects with moderate renal impairment. However, there was no clinically meaningful difference in the exposure of rimegepant in subjects with severe renal impairment compared to subjects with normal renal function (CLcr  $\geq$ 90mL/min). NURTEC ODT has not been studied in patients with end-stage renal disease (CLcr < 15 mL/min) [see *Use in Specific Populations (8.7)*].

#### *Hepatic Impairment*

In a dedicated clinical study comparing the pharmacokinetics of rimegepant in subjects with mild, moderate, and severe hepatic impairment to that with normal subjects (healthy matched control), the exposure of rimegepant ( $C_{max}$  and AUC) following single 75 mg dose was approximately 2-fold higher in subjects with severe impairment (Child-Pugh class C). There were no clinically meaningful differences in the exposure of rimegepant in subjects with mild (Child-Pugh class A) and moderate hepatic impairment (Child-Pugh class B) compared to subjects with normal hepatic function [see *Use in Specific Populations (8.6)*].

#### *Other Specific Populations*

No clinically significant differences in the pharmacokinetics of rimegepant were observed based on age, sex, race/ethnicity, body weight, or CYP2C9 genotype [see *Clinical Pharmacology (12.5)*].

#### Drug Interaction Studies

##### *In Vitro Studies*

- Enzymes

Rimegepant is a substrate of CYP3A4 and CYP2C9 (see *In Vivo Studies*). Rimegepant is not an inhibitor of CYP1A2, 2B6, 2C9, 2C19, 2D6, or UGT1A1 at clinically relevant concentrations.

However, rimegepant is a weak inhibitor of CYP3A4 with time-dependent inhibition.

Rimegepant is not an inducer of CYP1A2, CYP2B6, or CYP3A4 at clinically relevant concentrations.

- Transporters

Rimegepant is a substrate of P-gp and BCRP. (see *In Vivo Studies*).

Rimegepant is not a substrate of OATP1B1 or OATP1B3. Considering its low renal clearance, rimegepant was not evaluated as a substrate of the OAT1, OAT3, OCT2, MATE1, or MATE2-K.

Rimegepant is not an inhibitor of P-gp, BCRP, OAT1, or MATE2-K at clinically relevant concentrations. It is a weak inhibitor of OATP1B1 and OAT3. Rimegepant is an inhibitor of OATP1B3, OCT2, and MATE1. In a dedicated interaction study, concomitant administration of 75 mg rimegepant at steady state with metformin, a MATE1 transporter substrate, at steady state resulted in no clinically significant impact on either metformin pharmacokinetics or on glucose utilization. No clinical drug interactions are expected for NURTEC ODT with these OATP1B3 or OCT2, at clinically relevant concentrations.

##### *In Vivo Studies*

#### CYP3A4 Inhibitors

In a dedicated drug interaction study, concomitant administration of 75 mg rimegepant (single dose) with itraconazole, a strong CYP3A4 inhibitor, at steady state resulted in increased exposures of rimegepant (AUC by 4-fold and  $C_{max}$  by  $\sim$ 1.5-fold) [see *Drug Interactions (7.1)*]. No dedicated drug interaction study was conducted to assess the effect of concomitant administration of a weak inhibitor of CYP3A4 on the pharmacokinetics of rimegepant. The concomitant administration of rimegepant with a moderate inhibitor

of CYP3A4 may increase rimegepant exposures (AUC) by less than 2-fold [see *Drug Interactions (7.1)*]. Concomitant administration of rimegepant with a weak inhibitor of CYP3A4 is not expected to have a clinically significant impact on rimegepant exposures.

#### CYP3A Inducers

In a dedicated drug interaction study, concomitant administration of 75 mg rimegepant (single dose) with rifampin, a strong CYP3A4 inducer, at steady state resulted in decreased exposures of rimegepant (AUC by 80% and  $C_{max}$  by 64%), which may lead to loss of efficacy [see *Drug Interactions (7.2)*]. No dedicated drug interaction study was conducted to assess the effect of concomitant administration of a moderate or weak inducer of CYP3A4 on the pharmacokinetics of rimegepant. Since rimegepant is a moderately sensitive substrate for CYP3A4, drugs that are moderate inducers of CYP3A4 can also cause significant reduction in rimegepant exposure resulting in loss of efficacy [see *Drug Interactions (7.2)*]. Clinically significant interaction is not expected with concomitant administration of weak inducers of CYP3A4 and rimegepant.

#### CYP2C9 Inhibitors

In a dedicated drug interaction study, concomitant administration of 75 mg rimegepant (single dose) with fluconazole, a combined moderate CYP3A4 and CYP2C9 inhibitor, resulted in increased exposures of rimegepant (AUC by 1.8-fold) with no relevant effect on  $C_{max}$ .

Rimegepant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9. Increase in the exposure of rimegepant can be attributed to combined inhibition of CYP2C9 and CYP3A4 with fluconazole administration suggesting a minor contribution from CYP2C9. Thus, CYP2C9 inhibition alone is not expected to significantly affect rimegepant exposures.

#### P-gp and BCRP Inhibitors

In a dedicated drug interaction study, concomitant administration of NURTEC ODT with cyclosporine (a potent P-gp and BCRP inhibitor) and with quinidine (a potent P-gp inhibitor) resulted in an increase of similar magnitude in rimegepant exposure (AUC and  $C_{max}$  by 1.6 and 1.4 fold with cyclosporine, and by 1.6 and 1.7 fold with quinidine, respectively) [see *Drug Interactions (7.3)*]. Therefore, concomitant administration of NURTEC ODT with BCRP inhibitors is not expected to have a clinically significant impact on rimegepant exposures.

#### Other Drugs:

No significant pharmacokinetic interactions were observed when rimegepant was concomitantly administered with oral contraceptives (norgestromin, ethinyl estradiol), midazolam (a sensitive CYP3A4 substrate), metformin (a MATE1 substrate), or sumatriptan [see *Clinical Pharmacology (12.2)*].

### **12.5 Pharmacogenomics**

CYP2C9 activity is reduced in individuals with genetic variants such as the CYP2C9\*2 and CYP2C9\*3 alleles. Rimegepant  $C_{max}$  and AUC<sub>0-inf</sub> were similar in CYP2C9 intermediate metabolizers (i.e., \*1/\*2, \*2/\*2, \*1/\*3, n=43) as compared to normal metabolizers (i.e., \*1/\*1, N=72). Adequate PK data are not available from CYP2C9 poor metabolizers (i.e., \*2/\*3). Since the contribution of CYP2C9 to rimegepant metabolism is considered minor, CYP2C9 polymorphism is not expected to significantly affect its exposure.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

### Carcinogenesis

Oral administration of rimegepant to Tg.rasH2 mice (0, 10, 100, or 300 mg/kg/day) for 26 weeks and to rats (0, 5, 20, or 45 mg/kg/day) for 91-100 weeks resulted in no evidence of drug-induced tumors in either species. In rats, the plasma exposure (AUC) at the highest dose tested (45 mg/kg/day) was approximately 30 times that at the maximum recommended human dose (MRHD) of 75 mg/day.

### Mutagenesis

Rimegepant was negative in in vitro (bacterial reverse-mutation, chromosomal aberration in Chinese hamster ovary cells) and in vivo (rat micronucleus) assays.

### Impairment of Fertility

Oral administration of rimegepant (0, 30, 60, or 150 mg/kg/day) to male and female rats prior to and during mating and continuing in females to gestation day (GD) 7 resulted in reduced fertility at the highest dose tested. In a second fertility study testing lower doses (0, 5, 15, or 25 mg/kg/day), no adverse effects on fertility, uterine histopathology, or early embryonic development were observed. The no-effect dose for impairment of fertility and early embryonic development in rats (60 mg/kg/day) was associated with plasma drug exposures (AUC) approximately 30 times that in humans at the MRHD.

## 14 CLINICAL STUDIES

### 14.1 Acute Treatment of Migraine

The efficacy of NURTEC ODT for the acute treatment of migraine with and without aura in adults was demonstrated in a randomized, double-blind, placebo-controlled trial: Study 1 (NCT03461757). Patients in the study were randomized to receive 75 mg of NURTEC ODT (N=732) or placebo (N=734).

Patients were instructed to treat a migraine of moderate to severe headache pain intensity.

Rescue medication (i.e., NSAIDs, acetaminophen, and/or an antiemetic) was allowed 2 hours after the initial treatment. Other forms of rescue medication such as triptans were not allowed within 48 hours of initial treatment. Approximately 14% of patients were taking preventive medications for migraine at baseline. None of the patients in Study 1 were on concomitant preventive medication that act on the CGRP pathway.

The primary efficacy analyses were conducted in patients who treated a migraine with moderate to severe pain. NURTEC ODT 75 mg demonstrated an effect on pain freedom and most bothersome symptom (MBS) freedom at two hours after dosing, compared to placebo. Pain freedom was defined as a reduction of moderate or severe headache pain to no headache pain, and MBS freedom was defined as the absence of the self-identified MBS (i.e., photophobia, phonophobia, or nausea). Among patients who selected an MBS, the most commonly selected symptom was photophobia (54%), followed by nausea (28%), and phonophobia (15%). In Study 1, the percentage of patients achieving headache pain freedom and MBS freedom two hours after a single dose was statistically significantly greater in patients who received NURTEC ODT compared to those who received placebo (Table 1).

**Table 1: Efficacy Endpoints for the Acute Treatment of Migraine in Study 1**

	Study 1	
	NURTEC ODT 75 mg	Placebo
<b>Pain Free at 2 hours</b>		
n/N*	142/669	74/682

% Responders	21.2	10.9
Difference from placebo (%)	10.3	
p-value		<0.001
<b>MBS Free at 2 hours</b>		
n/N*	235/669	183/682
% Responders	35.1	26.8
Difference from placebo (%)	8.3	
p-value		0.001

\*n=number of responders/N=number of patients in that treatment group

Figure 1 presents the percentage of patients achieving migraine pain freedom within 2 hours following treatment in Study 1.

**Figure 1: Percentage of Patients Achieving Pain Freedom within 2 Hours in Study 1**





Figure 2 presents the percentage of patients achieving MBS freedom within 2 hours in Study 1.

**Figure 2: Percentage of Patients Achieving MBS Freedom within 2 Hours in Study 1**



In Study 1, statistically significant effects of NURTEC ODT compared to placebo were demonstrated for the additional efficacy endpoints of pain relief at 2 hours, sustained pain freedom 2-48 hours, use of rescue medication within 24 hours, and the percentage of patients reporting normal function at two hours after dosing (Table 2). Pain relief was defined as a reduction in migraine pain from moderate or severe severity to mild or none. The measurement of the percentage of patients reporting normal function at two hours after dosing was derived from a single item questionnaire, asking patients to select one response on a 4-point scale; normal function, mild impairment, severe impairment, or required bedrest.

**Table 2. Additional Acute Treatment of Migraine Efficacy Endpoints in Study 1**

	Study 1	
	NURTEC ODT 75 mg	Placebo
<b>Pain Relief at 2 hours</b>		
n/N*	397/669	295/682
% Responders	59.3	43.3
Difference from placebo	16.1	
p-value		<0.001
<b>Sustained Pain Freedom 2-48 hours</b>		
n/N*	90/669	37/682
% Responders	13.5	5.4
Difference from placebo	8.0	
p-value		<0.001
<b>Use of Rescue Medication within 24 hours**</b>		
n/N*	95/669	199/682
% Responders	14.2	29.2

Difference from placebo	-15.0	
p-value		<0.001
<b>Percentage of Patients Reporting Normal Function at 2 hours</b>		
n/N*	255/669	176/682
% Responders	38.1	25.8
Difference from placebo	12.3	
p-value		<0.001

\*n=number of responders/N=number of patients in that treatment group

\*\*This analysis includes only the use of NSAIDs, acetaminophen, or antiemetics, within 24 hours post-dose; the use of triptans, or other acute migraine medication, was not allowed.

The incidence of photophobia and phonophobia was reduced following administration of NURTEC ODT 75 mg as compared to placebo.

## 14.2 Preventive Treatment of Episodic Migraine

The efficacy of NURTEC ODT for the preventive treatment of episodic migraine in adults was demonstrated in one randomized, double-blind, placebo-controlled trial of a different oral dosage form of rimegepant (Study 2; NCT03732638).

Study 2 enrolled adult patients with at least a 1-year history of migraine (with or without aura). Patients experienced an average of 10.9 headache days during the 28-day observational period, which included an average of 10.2 migraine days, prior to randomization into the trial. Patients were randomized to receive every other day dosing of rimegepant 75 mg (N=373) or placebo (N=374) for 12 weeks. Patients were allowed to use acute headache treatments (i.e., triptans, NSAIDs, acetaminophen, antiemetics, muscle relaxants, and aspirin) as needed. Approximately 10% of patients were taking one preventive medication for migraine at baseline. The use of a concomitant medication that acts on the CGRP pathway was not permitted for either the acute or preventive treatment of migraine.

The study excluded patients with myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke, or transient ischemic attack within six months of screening.


The primary efficacy endpoint for Study 2 was the change from baseline in the mean number of monthly migraine days (MMDs) during Weeks 9 through 12 of the double-blind treatment phase.

The percentage of patients who achieved at least a 50% reduction from baseline in moderate to severe MMDs during Weeks 9 through 12 of the double-blind treatment phase compared to placebo was also evaluated. Rimegepant 75 mg dosed every other day demonstrated statistically significant improvements for these efficacy endpoints compared to placebo, as summarized in Table 3.

**Table 3: Efficacy Endpoints for the Preventive Treatment of Episodic Migraine in Study 2**


	<b>Rimegepant 75 mg Every Other Day</b>	<b>Placebo Every Other Day</b>
<b>Monthly Migraine Days (MMD), Weeks 9-12</b>	<b>N=348</b>	<b>N=347</b>
Change from baseline	-4.3	-3.5
Change from placebo	-0.8	
p-value	0.010	
<b>≥ 50% Responders (Moderate to Severe MMDs), Weeks 9-12</b>	<b>N=348</b>	<b>N=347</b>
% Responders	49.1	41.5
Difference from placebo	7.6	
p-value	0.044	

**Figure 3: Change from Baseline in Monthly Migraine Days in Study 2<sup>a</sup>**



<sup>a</sup>Least-square means and 95% confidence intervals are presented.


**Figure 4: Distribution of Change from Baseline in Mean Monthly Migraine Days at Month 3 by Treatment Group in Study 2a**



<sup>a</sup>Figure excludes patients with missing data.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

### 16.1 How Supplied

NURTEC ODT 75 mg orally disintegrating tablets are white to off-white, circular, debossed with the symbol , and supplied in cartons containing a blister pack of 2 or 8 orally disintegrating tablets. Each ODT contains 75 mg rimegepant. Not all pack sizes may be marketed.

### 16.2 Storage and Handling

Store below 25°C. Store in the original package in order to protect from moisture. The expiry date of the product is indicated on the packaging materials.

## 17. LICENSE HOLDER

Pfizer Pharmaceuticals Israel Ltd. 9 Shenkar St. Hertzliya 4672509.

Nurtec LPD CC 27 May 2026

**18. REGISTRATION NUMBER**

Nurtec ODT: 166-81-36535-99

Revised in 05/2026.